Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (15 items missing)
No data available for the selected time periods
in million USD Q1 '15Q2 '15Q3 '15Q4 '15Q1 '16
Patient service operating revenues
150
n/a
n/a
n/a
174
Provision for uncollectible accounts
-1
n/a
n/a
n/a
-1
Net patient service operating revenues
149
n/a
n/a
n/a
172
Patient care costs
92
n/a
n/a
n/a
105
General and administrative
17
n/a
n/a
n/a
21
Transaction-related costs (Note 13)
0
n/a
n/a
n/a
0
Depreciation and amortization
8
n/a
n/a
n/a
8
Total operating expenses
117
n/a
n/a
n/a
135
Operating Income
32
n/a
n/a
n/a
37
Interest expense, net
-11
n/a
n/a
n/a
-12
Income before income taxes
21
n/a
n/a
n/a
25
Income tax expense
2
n/a
n/a
n/a
3
Net income
19
n/a
n/a
n/a
23
Less: Net income attributable to noncontrolling interests
-16
n/a
n/a
n/a
-19
Net income attributable to American Renal Associates Holdings Inc.
3
n/a
n/a
n/a
4
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (32 items missing)
No data available for the selected time periods
in million USD Q1 '15Q2 '15Q3 '15Q4 '15Q1 '16
Assets
Cash
n/a
n/a
n/a
91
96
Accounts receivable, less allowance for doubtful accounts of $7,949 and $7,435, respectively
n/a
n/a
n/a
77
76
Inventories
n/a
n/a
n/a
4
6
Prepaid expenses and other current assets
n/a
n/a
n/a
19
20
Income tax receivable
n/a
n/a
n/a
3
3
Total current assets
n/a
n/a
n/a
194
199
Property and equipment, net of accumulated depreciation of $144,733 and $138,163, respectively
n/a
n/a
n/a
143
151
Intangible assets, net of accumulated depreciation of $22,466 and $22,378, respectively
n/a
n/a
n/a
26
26
Other long-term assets
n/a
n/a
n/a
7
7
Goodwill
n/a
n/a
n/a
569
569
Total assets
n/a
n/a
n/a
938
952
Liabilities and owners' equity
Accounts payable
n/a
n/a
n/a
23 22571000
24 23857000
Accrued compensation and benefits
n/a
n/a
n/a
23 22504000
21 21496000
Accrued expenses and other current liabilities
n/a
n/a
n/a
27 26788000
31 31110000
Current portion of long-term debt
n/a
n/a
n/a
26 25610000
27 27171000
Total current liabilities
n/a
n/a
n/a
97 97473000
104 103634000
Long-term debt, less current portion
n/a
n/a
n/a
657 657372000
661 661369000
Other long-term liabilities
n/a
n/a
n/a
9 9483000
10 9927000
Deferred tax liabilities
n/a
n/a
n/a
15 15029000
15 15096000
Total liabilities
n/a
n/a
n/a
779 779357000
790 790026000
Commitments and contingencies (Note 12)
n/a
n/a
n/a
0 0
0 0
Noncontrolling interests subject to put provisions
n/a
n/a
n/a
108 108211000
107 107414000
Preferred stock, $0.01 par value, 1,000,000 shares authorized; none issued
n/a
n/a
n/a
0 0
0 0
Common stock, $0.01 par value, 29,770,000 shares authorized, 22,213,967 issued and outstanding
n/a
n/a
n/a
0 98000
0 98000
Additional paid-in capital
n/a
n/a
n/a
0 0
0 457000
Receivable from noncontrolling interests
n/a
n/a
n/a
-1 -529000
-1 -605000
Accumulated deficit
n/a
n/a
n/a
-128 -128261000
-125 -124505000
Accumulated other comprehensive loss, net of tax
n/a
n/a
n/a
-1 -501000
0 -401000
Total American Renal Associates Holdings, Inc. deficit
n/a
n/a
n/a
-129 -129193000
-125 -124956000
Noncontrolling interests not subject to put provisions
n/a
n/a
n/a
180 179903000
180 179965000
Total equity
n/a
n/a
n/a
51 50710000
55 55009000
Total liabilities and equity
n/a
n/a
n/a
938 938278000
952 952449000
Remarks restated on n/a restated on n/a restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (31 items missing)
No data available for the selected time periods
in million USD Q1 '15Q2 '15Q3 '15Q4 '15Q1 '16
Net income
19
n/a
n/a
n/a
23
Depreciation and amortization
8
n/a
n/a
n/a
8
Amortization of discounts, fees and deferred financing costs
1
n/a
n/a
n/a
1
Stock-based compensation
0
n/a
n/a
n/a
0
Excess tax benefit for stock options exercised, net
0
n/a
n/a
n/a
0
Deferred taxes
2
n/a
n/a
n/a
0
Non-cash charge related to interest rate swap
0
n/a
n/a
n/a
1
Non-cash rent charges
0
n/a
n/a
n/a
1
Accounts receivable
-5
n/a
n/a
n/a
1
Inventories
0
n/a
n/a
n/a
-1
Prepaid expenses and other current assets
2
n/a
n/a
n/a
0
Other assets
-1
n/a
n/a
n/a
0
Accounts payable
-1
n/a
n/a
n/a
1
Accrued compensation and benefits
3
n/a
n/a
n/a
-1
Accrued expenses and other liabilities
0
n/a
n/a
n/a
4
Cash provided by operating activities
28
n/a
n/a
n/a
37
Purchases of property, equipment and intangible assets
-11
n/a
n/a
n/a
-16
Cash paid for acquisitions
-1
n/a
n/a
n/a
0
Cash used in investing activities
-12
n/a
n/a
n/a
-16
Proceeds from term loans
6
n/a
n/a
n/a
12
Payments on long-term debt
-4
n/a
n/a
n/a
-7
Payments on capital lease obligations
0
n/a
n/a
n/a
0
Excess tax benefit from stock option exercises
0
n/a
n/a
n/a
0
Payments of deferred offering costs
0
n/a
n/a
n/a
0
Common stock repurchases for tax withholdings of net settlement equity awards
0
n/a
n/a
n/a
0
Distributions to noncontrolling interests
-18
n/a
n/a
n/a
-21
Contributions from noncontrolling interests
1
n/a
n/a
n/a
2
Purchases of noncontrolling interests
-2
n/a
n/a
n/a
0
Proceeds from sales of additional noncontrolling interests
0
n/a
n/a
n/a
0
Cash used in financing activities
-17
n/a
n/a
n/a
-15
Increase (Decrease) in Cash
-1
n/a
n/a
n/a
5
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,